Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Jefferies Financial Group increased their FY2018 earnings per share estimates for Halozyme Therapeutics in a note issued to investors on Tuesday, November 6th. Jefferies Financial Group analyst E. Yang now anticipates that the biopharmaceutical company will post earnings of ($0.54) per share for the year, up from their previous estimate of ($0.85). Jefferies Financial Group also issued estimates for Halozyme Therapeutics’ Q4 2018 earnings at $0.00 EPS, FY2019 earnings at ($0.47) EPS, FY2020 earnings at ($0.43) EPS, FY2021 earnings at $0.29 EPS and FY2022 earnings at $0.96 EPS.

Several other equities research analysts have also issued reports on HALO. BMO Capital Markets raised their target price on shares of Halozyme Therapeutics from $19.00 to $21.00 and gave the stock a “market perform” rating in a report on Wednesday, August 8th. Cantor Fitzgerald began coverage on shares of Halozyme Therapeutics in a report on Wednesday, August 22nd. They set an “overweight” rating and a $27.00 price objective for the company. BidaskClub lowered shares of Halozyme Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, September 19th. ValuEngine upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 3rd. Finally, Piper Jaffray Companies began coverage on shares of Halozyme Therapeutics in a report on Thursday, October 18th. They set a “hold” rating and a $17.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $20.78.

Halozyme Therapeutics stock opened at $15.89 on Friday. The stock has a market capitalization of $2.30 billion, a PE ratio of 35.31 and a beta of 1.88. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.09 and a quick ratio of 3.43. Halozyme Therapeutics has a 12-month low of $14.33 and a 12-month high of $21.48.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. The firm had revenue of $25.60 million during the quarter, compared to analyst estimates of $30.42 million. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.87%. The business’s revenue was down 59.8% on a year-over-year basis. During the same quarter last year, the business earned $0.02 EPS.

In related news, major shareholder Randal J. Kirk sold 303,168 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $17.36, for a total transaction of $5,262,996.48. Following the completion of the sale, the insider now owns 3,562,388 shares in the company, valued at approximately $61,843,055.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Randal J. Kirk sold 161,246 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $17.15, for a total transaction of $2,765,368.90. Following the sale, the insider now owns 3,562,388 shares of the company’s stock, valued at approximately $61,094,954.20. The disclosure for this sale can be found here. Insiders have sold a total of 2,793,946 shares of company stock valued at $49,250,429 in the last quarter. 16.80% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in HALO. Cubist Systematic Strategies LLC raised its holdings in shares of Halozyme Therapeutics by 69.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 22,346 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 9,134 shares in the last quarter. MERIAN GLOBAL INVESTORS UK Ltd bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $21,690,000. Rhumbline Advisers raised its holdings in shares of Halozyme Therapeutics by 7.0% in the 2nd quarter. Rhumbline Advisers now owns 132,784 shares of the biopharmaceutical company’s stock valued at $2,240,000 after purchasing an additional 8,703 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Halozyme Therapeutics by 76.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 643,822 shares of the biopharmaceutical company’s stock valued at $10,862,000 after purchasing an additional 277,953 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of Halozyme Therapeutics by 60.3% in the 2nd quarter. Wells Fargo & Company MN now owns 535,697 shares of the biopharmaceutical company’s stock valued at $9,038,000 after purchasing an additional 201,507 shares in the last quarter. Institutional investors own 84.63% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Article: Stock Symbol

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.